Optimistically, we further explored the role of NAF-1 as a novel molecular target for improving the efficacy of the current chemotherapeutic regimens used in patients with pancreatic cancer and improving their clinical prognosis. This evidence concerns the gene NAF1 and familial pancreatic carcinoma.